Page 2507 - Williams Hematology ( PDFDrive )

2478 Index Index 2479

Plasmin (Cont.): release, 1852f, 1856 discoid, 1835f
inhibitors, 2307–2308 synthesis, 1840 disorders, 1991. See also
nonfibrinolytic vascular functions, 1974 in thrombosis and hemostasis, 1979t Thrombocythemia;
platelet function and, 2078 Platelet-activating factor (PAF) receptor Thrombocytopenia; specific type
as tissue remodeler, 2311 defect, 2057 acquired, 2073–2086
Plasminogen (Plg), 2303 Platelet antigens (human). See Human in acquired von Willebrand
activation, 2304f, 2310–2311 platelet antigens (HPAs) syndrome, 2082–2083
functions, 2303 Platelet count, 17–18 antiplatelet antibodies and,
properties, 2304–2305t in acute lymphoblastic leukemia, 1510, 2084–2085
structure, 2303 1510t in Bartter syndrome, 2086
Plasminogen activator inhibitor (PAI)-1, bleeding risk and, 2382–2383 cardiopulmonary bypass and,
1975, 2308 in chronic myelogenous leukemia, 1445, 2085–2086
activities, 1923, 2308 1445f in chronic myeloproliferative
characteristics, 2305t, 2308 in disseminated intravascular coagulation, neoplasms, 2079–2081
in disseminated intravascular coagulation, 2205t in disseminated intravascular
2206, 2208 in essential thrombocythemia, 1310, 1311t coagulation, 2086, 2200–2201
in fibrinolysis regulation, 1845, 2202, 2311 in hemostatic disorders, 1988, 1989f drug-induced, 2073–2079
gene expression, 2308 in heparin-induced thrombocytopenia, in dysproteinemias, 2082
plasmin generation and, 1973–1974 2028 in hemorrhagic fevers, 2086
in platelets, 1845 in hepatic disease, 2191 in hepatic disease, 2086, 2191
Plasminogen activator inhibitor (PAI)-1 in immune thrombocytopenia, 2002 in iron deficiency, 633
deficiency, 2318 normal, 1994, 2035 in leukemias and myelodysplastic
Plasminogen activator inhibitor (PAI)-2, platelet destruction and, 2381–2382, 2382f syndromes, 1353, 2081–2082
2305t, 2308, 2312 during pregnancy, 119, 2010 in polycythemia vera, 1295
Plasminogen activators, 2303–2307 in primary myelofibrosis, 1326 in uremia, 2083–2084
accessory, 2307 reference ranges, 18t, 19f hereditary, 1996–1997, 2039–2062.
comparison, 2304–2305t, 2313t technique, 1994 See also specific disorders
fibrinolysins, 2307 transfusion threshold, 2383 adhesion receptor abnormalities,
in fibrinolytic therapy. See Fibrinolytic Platelet-derived growth factor (PDGF), 1322, 2040t, 2042–2052
therapy 1845, 1848 approach to, 1996, 2040–2042, 2041f
genes, 2306f, 2307t Platelet-endothelial cell adhesion molecule-1 classification, 1996, 1998t, 2039–2040
physiologic functions, 2307 (PECAM-1, CD31) clinical features, 1996, 2040
tissue-type. See Tissue-type plasminogen in inflammatory response, 1977t, 1978 coagulant activity abnormalities,
activator (t-PA) in leukocyte adhesion, 283 2040t, 2058–2059
urokinase. See Urokinase plasminogen in monocytes, 1052f cytoskeletal linking protein
activator (u-PA) in neutrophil function, 2273 abnormalities, 2040t, 2059–2060
Plasminogen receptors, 2308 in platelet adhesion and aggregation, 1868 cytoskeletal structural protein
Plasmodium falciparum Src activation and, 1884 abnormalities, 2040t, 2059
glycophorins and, 664, 2340 structure, 1858–1859t, 1868 granule abnormalities, 2040t,
life cycle, 815 Platelet factor 4. See CXCL4 (platelet factor 4) 2052–2056, 2052f
malaria and. See Malaria Plateletpheresis, 2368 laboratory features, 1996–1997
mannose-binding lectin deficiency and, Platelet-rich plasma method, 2386, 2386f in pregnancy, 2062
1017 Platelets. See also Thrombopoiesis signaling and secretion abnormalities,
pyruvate kinase deficiency and, 704 activation, 2293 2040t, 2056–2058
Southeast Asian ovalocytosis and, 680 adhesion, aggregation, and thrombus surgical management in, 2062
thalassemias and, 728 formation, 1830–1831f, therapy, 2061–2062
TIRAP and, 1054 1830–1834, 1852f, 1857f, 1940 transcription factor mutations, 2040t,
Plasmodium knowlesi, 2340 alloimmunization, 2084–2085 2060–2061
Plasmodium ovale, 815 antibody-induced agglutination, 1995 energy metabolism, 1839–1840
Plasmodium vivax, 728, 815, 817, 817f, 2340 antiphospholipid antibodies and, 2237 formation, 1820–1821. See also
Platelet-activating factor (PAF) automated analysis, 16–17, 18t, 19f Megakaryopoiesis
in inflammatory response, 281, 284t, 286t, calcium homeostasis, 1837f functions
289, 1979t CD39 inhibition, 1971 in hemostasis, 2039
as lipid mediator, 1878 characteristics, 1993 in inflammation and infection,
neutrophils and, 1007, 1016 clearance, 1993 1855–1857, 1857f
production, 1977 coagulant activity, 1854 in newborns, 107–108

Kaushansky_index_p2393-2506.indd 2478 9/21/15 3:22 PM